FDA clears Alzheimer’s blood test: a game changer for biomarker-driven trials

AbbVie submitted an NDA to the FDA following Ph3 data of Tavapadon targeting Parkinson’s

BMS granted FDA Fast Track Designation for BMS-986446 - an anti-microtubule binding region tau antibody currently in Ph2 targeting Alzheimer’s

C2N Diagnostics submitted regulatory filing to the FDA for their Alzheimer’s blood test

Herantis Pharma announced positive topline Ph1b data evaluation HER-096 targeting PD

Matthew Mandeville

Applications & BD Manager BrainXell

Wednesday 4th February 2026

Human iPSC-derived Neurons & Glia to Model Alzheimer’s & Parkinson’s Disease

11:30 am

BrainXell is a leading provider of hiPSC-derived neurons and glia, working with over 75% of the world’s largest pharmaceutical companies.

Comprehensive off-the-shelf portfolio featuring key Alzheimer’s-related mutations (APOE, TREM2, APP, PSEN1, etc.) with matched isogenic controls.
New dopaminergic neuron differentiation protocol generates high-purity cells capable of dopamine secretion by DIV 14
Robust, scalable manufacturing processes generate billions of cells, and flexible custom workflows deliver the same high-quality cell types from any customer-supplied iPSC line